J Korean Med Sci.  2011 Feb;26(2):231-236. 10.3346/jkms.2011.26.2.231.

GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer

• Ha YS
• Yan C
• Jeong P
• Kim WT
• Yun SJ
• Yi Kim I
• Moon SK
• Kim WJ

• KMID: 1782111
• DOI: http://doi.org/10.3346/jkms.2011.26.2.231

Abstract

Tissue genotyping is more useful approach than using blood genomic DNA, which can reflect the effects of the somatic mutations in cancer. Although polymorphisms in glutathione S-transferase (GST) have been associated with the risk of bladder cancer (BC) development, few reports provide information about the prognosis of BC. We investigated glutathione S-transferase mu (GSTM1) and glutathione S-transferase theta (GSTT1) genotypes using genomic DNA from primary 165 BC tissue samples to assess the association with disease prognosis. DNA samples from tumor were analyzed by multiplex polymerase chain reaction (PCR). The results were compared with clinicopathological parameters. The prognostic significance of the GSTs was evaluated by Kaplan-Meier and multivariate Cox regression model. Kaplan-Meier estimates revealed significant differences in time to tumor recurrence according to the GSTM1 tissue genotype (P = 0.038) in non-muscle invasive bladder cancer (NMIBC). Multivariate Cox regression analysis also revealed that the tissue GSTM1 genotype (hazards ratio [HR]: 0.377, P = 0.031) was an independent predictor of bladder tumor recurrence in NMIBC. This identification of GSTM1 tissue genotype as a prognosticator for determining recurrence in NMIBC should prove highly useful in a clinical setting.

Keyword

Urinary Bladder Neoplasms; Tumor Markers, Biological; GSTM1; Glutathione S-Transferase T1

MeSH Terms

Aged
*Genotype
Glutathione Transferase/*genetics
Humans
Isoenzymes/*genetics
Kaplan-Meier Estimate
Middle Aged
Prognosis
Proportional Hazards Models
Recurrence
Tumor Markers, Biological/metabolism
Urinary Bladder Neoplasms/diagnosis/*genetics/pathology/*prevention & control

Figure

• 

  Fig. 1 Electrophoretic findings of GSTM1 and GSTT1, Lane M: molecular size marker (100 bp DNA ladder); Lane 1: GSTM1-null/GSTT1-null type; Lane 2: GSTM1-null/GSTT1-positive type; Lane 3: GSTM1-positive/GSTT1-null type; Lane 4: GSTM1-positive/GSTT1-positive type.

• 

  Fig. 2 Kaplan-Meier estimate curves predict the probability of recurrence according to the GSTM1 genotype in patients with non-muscle invasive bladder cancer.

Reference

1. Hirao Y, Kim WJ, Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol. 2009. 19:494–499.

2. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003. 15:227–233.

3. Kim TH, Jo SW, Lee YS, Kim YJ, Lee SC, Kim WJ, Yun SJ. Forkhead box O-class 1 and forkhead box G1 as prognostic markers for bladder cancer. J Korean Med Sci. 2009. 24:468–473.

4. Ha YS, Kim MJ, Yoon HY, Kang HW, Kim YJ, Yun SJ, Lee SC, Kim WJ. mRNA Expression of S100A8 as a prognostic marker for progression of non-muscle-invasive bladder cancer. Korean J Urol. 2010. 51:15–20.

5. Kim WJ, Lee HL, Lee SC, Kim YT, Kim H. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol. 2000. 164:209–213.

6. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 1996. 56:3915–3925.

7. Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev. 2009. 32:416–423.

8. Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N. EPICURO/Spanish Bladder Cancer Study investigators. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol. 2010. 57:283–292.

9. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg. 2002. 87:13–15.

10. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. International Histologic Classification of Tumors. 1973. Geneva: World Health Organzation.

11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008. 54:303–314.

12. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007. 178:2314–2330.

13. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009. 55:815–825.

14. Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996. 347:295–297.

15. Kim WJ, Kim H, Kim CH, Lee MS, Oh BR, Lee HM, Katoh T. GSTT1-null genotype is a protective factor against bladder cancer. Urology. 2002. 60:913–918.

16. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993. 85:1159–1164.

17. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res. 1999. 5:4079–4084.

18. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001. 61:1265–1268.

19. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998. 4:829–834.

20. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008. 180:1141–1145.

21. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010. 9:3.

22. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005. 5:713–725.

23. Kim YJ, Ha YS, Kim SK, Yoon HY, Lym MS, Kim MJ, Moon SK, Choi YH, Kim WJ. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res. 2010. 16:2131–2137.

24. Ha YS, Yan C, Park C, Yun SJ, Moon SK, Choi YH, Kim WJ. GSTT1: A marker of the aggressiveness of bladder cancer. Urol Int. 2010. doi: 10.1159/000321689.

25. Srivastava DS, Mishra DK, Mandhani A, Mittal B, Kumar A, Mittal RD. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol. 2005. 48:339–344.

26. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003. 21:1315–1330.

27. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006. 175:1641–1644.

28. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol. 2004. 172:70–75.

29. Ramani VA, Bromage SJ, Clarke NW. A contemporary standard for morbidity and outcome after radical cystectomy. BJU Int. 2009. 104:628–632.

30. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organconfined TCC at radical cystectomy. Eur Urol. 2007. 51:152–160.